Tag Archive for: dostarlimab

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

/in

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC Geneva, Switzerland and Amsterdam, […]

Read more

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

/in

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

Read more